Alterity Therapeutics Ltd has released a press release.
Appendix 4E and 2025 Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- Response to ASX Query Letters
- Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
- Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
- Positive ATH434 Results from Open-Label Phase 2 Trial in MSA
- Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
Later from Alterity Therapeutics
- Alterity Therapeutics to Present at the Biotech Showcase
- Trading Halt
- Alterity Therapeutics Raises A$20.0 million in Strategic Placement
- Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
- Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics